Ultra-processed food (UPF) consumption have increased in the world during the last decades since they are hyper-palatable, cheap and ready-to-consume products. However, uncertainty exists on their impact on health. We conducted a systematic review and meta-analysis evaluating the association of UPF consumption with the all-cause mortality risk. Five bibliographic databases were searched for relevant studies. Random effects models were used to calculate pooled relative risks (RR) and 95% confidence intervals (CI). Of 6,951 unique citations, 40 unique prospective cohort studies comprising 5,750,133 individuals were included. Publication date of the included studies ranged from 1984 to2021. Compared to low consumption, highest consumption of UPF (RR=1.29, 95% CI 1.17-1.42), sugar-sweetened beverages (SSB) (RR=1.11, 95% CI, 1.04-1.18), artificially sweetened beverages (ASB) (RR=1.14, 95% CI, 1.05-1.22) and processed meat/red meat (RR=1.15, 95% CI, 1.10-1.21) were significantly associated with increased risk of mortality. On the contrary, breakfast cereals were associated with a lower mortality risk (RR=0.85, 95% CI, 0.79-0.92). Conclusion: This meta-analysis suggests that high consumption of UPF, SSB, ASB, processed meat and processed red meat might increase all-cause mortality, while breakfast cereals might decrease it. Future studies are needed to address lack of standardized methods in UPF categorization.

Summary Flaxseed consumption may be inversely associated with obesity; however, findings of available randomized controlled trials (RCTs) are conflicting. The present study aimed to systematically review and analyse RCTs assessing the effects of flaxseed consumption on body weight and body composition. PubMed, Medline via Ovid, SCOPUS, EMBASE and ISI Web of Sciences databases were searched up to November 2016. Mean changes in body composition indices including body weight, body mass index (BMI) and waist circumference were extracted. Effect sizes were expressed as weighted mean difference (WMD) and 95% confidence intervals (CI). Heterogeneity between studies was assessed with the I2 test. Publication bias and subgroup analyses were also performed. The quality of articles was assessed via the Jadad scale. A total of 45 RCTs were included. Meta‐analyses suggested a significant reduction in body weight (WMD: −0.99 kg, 95% CI: −1.67, −0.31, p = 0.004), BMI (WMD: −0.30 kg m−2, 95% CI: −0.53, −0.08, p = 0.008) and waist circumference (WMD: −0.80 cm, 95% CI: −1.40, −0.20, p = 0.008) following flaxseed supplementation. Subgroup analyses showed that using whole flaxseed in doses ≥30 g d−1, longer‐term interventions (≥12 weeks) and studies including participants with higher BMI (≥ 27 kg m−2) had positive effects on body composition. Whole flaxseed is a good choice for weight management particularly for weight reduction in overweight and obese participants.

Background This study aimed to compare the effects of sesame (SO), canola (CO), and sesame‐canola (SCO: a blend) oils on glycaemic control markers and liver function enzymes in adults with type 2 diabetes. Methods In this randomized, triple‐blind, three‐way, cross‐over clinical trial, participants replaced their usual oil with the intervention oils for 9 weeks. Serum fasting blood sugar, fasting serum insulin (FSI), insulin resistance (HOMA2‐IR), beta‐cell function (HOMA2‐%B), insulin sensitivity (HOMA2‐%S), quantitative insulin sensitivity check index (QUICKI), as well as serum liver function enzymes were measured at baseline and end of intervention periods. Results Ninety‐two participants completed all treatment periods. After adjusting for confounders, all treatment oils resulted in significant improvements in FSI and HOMA2‐%S (p < 0.05). SO and SCO led to favourable changes in HOMA2‐IR and QUICKI (p < 0.05). Following CO and SCO, there was a significant decrease in HOMA2‐%B (p < 0.05). The sex‐stratified analysis revealed that FSI and HOMA2‐IR were decreased after SO compared to CO in males (p = 0.024). Serum gamma‐glutamyltransferase (GGT) was significantly lower following SO compared to CO in females (p = 0.02), however, the difference in change values was not significant (p = 0.058). Conclusions SO consumption appears to improve glycaemic control markers in males and serum GGT in females compared with CO in patients with type 2 diabetes (registration code: IRCT2016091312571N6).

Whole flaxseed, but not flaxseed oil and lignan extract, has significant effects on improving glycemic control. Further studies are needed to determine the benefits of flaxseed on glycemic parameters.

No abstract

A number of clinical trials have examined the effect of canola oil (CO) on body composition in recent years; however, the results have been inconsistent. The present investigation aims to examine the effect of CO on body weight (BW) and body composition using a systematic review and meta-analysis of controlled clinical trials. Online databases including PubMed, Scopus, and Google Scholar were searched up to February, 2018 for randomized controlled clinical trials that examined the effect of CO on anthropometric measures and body composition indexes in adults. The Cochrane Collaboration's tool was used to assess the risk of bias in individual studies. A random-effects model was used to evaluate the effect of CO consumption on several outcomes: BW, body mass index, waist circumference, hip circumference, waist-to-hip ratio, android-to-gynoid ratio, and body lean and fat mass. In total, 25 studies were included in the systematic review. The meta-analysis revealed that CO consumption reduces BW [weighted mean difference (WMD) = −0.30 kg; 95% CI: −0.52, −0.08 kg, P = 0.007; n = 23 effect sizes], particularly in participants with type 2 diabetes (WMD = −0.63 kg; 95% CI: −1.09, −0.17 kg, P = 0.007), in studies with a parallel design (WMD = −0.49 kg; 95% CI: −0.85, −0.14 kg, P = 0.006), in nonfeeding trials (WMD = −0.32 kg; 95% CI: −0.55, −0.09 kg, P = 0.006), and when compared with saturated fat (WMD = −0.40 kg; 95% CI: −0.74, −0.06 kg, P = 0.019). CO consumption did not significantly affect any other anthropometric measures or body fat markers (P > 0.05). Although CO consumption results in a modest decrease in BW, no significant effect was observed on other adiposity indexes. Further well-constructed clinical trials that target BW and body composition as their primary outcomes are needed.

No abstract

No abstract